Global hypercalcemia treatment market revenues are anticipated to reach US$ 9.64 Bn in 2017, up from US$ 7.86 Bn in 2015. Increasing prevalence of hyperparathyroidism-related hypercalcemia and rising incidence of multiple myeloma are major factors expected to fuel growth of the global hypercalcemia treatment market over the forecast period. Availability of drug therapy alternatives over surgeries and favourable reimbursement policies are key factors expected to fuel global market growth.
Hospitals remain the largest distribution channel in the hypercalcemia market in terms of revenue contribution, accounting for around 39% share to the global market in 2015. Rapid diagnosis and easy availability of hypercalcemia drugs are key factors attributed to increasing revenue from the hospitals end user segment, and hospitals are expected to continue to remain the largest distribution channel for hypercalcemia treatment in the long-term.
To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-1320
Bisphosphonates product type segment is estimated to continue to account for relatively higher revenue share to the global market, at over 67% in 2016 end. U.S. FDA approval of denosumab (Xgeva) for treating hypercalcemia of malignancy refractory in 2014 has boosted the use of biophosphonates. Glucocorticoids and calcimimetics segments are also anticipated to witness steady revenue growth in the near future.
North America and Western Europe are among the leading markets for hypercalcemia treatment, with the former accounting for revenue share of 46% in 2015. The North America hypercalcemia treatment market is anticipated to be valued at US$ 4.39 Bn in 2017, up from US$ 3.61 Bn in 2015. The market in North America is dominated by the U.S. Higher prevalence of malignancy-related hypercalcemia among cancer patients in North America will continue to influence market growth in the near future.
Amgen Inc., Novartis AG, and Teva Pharmaceuticals Industries Ltd., Pfizer Inc., and F.Hoffmann-La Roche Ltd. are among the leading players in the global hypercalcemia market. The U.S. remains a lucrative market for majority of leading players; foraying into emerging markets of Asia and Africa is a key focus area for global players.
Long-term Outlook: The global hypercalcemia market is anticipated to register a CAGR of 11.2% in terms of revenue during forecast period 2016–2026, and reach a value of US$ 25.23 Bn by 2026.
For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-1320
Why Future Market Insights?
• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years
Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario
About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com